Our strategic partners

RTW Investments (RTW) is a global, full life-cycle investment firm and company builder that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors. As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to support emerging medical therapies and the companies and/or academics developing them.

RTW founded CORXEL in 2019 and has been supporting the company with an excellent incubation team. RTW previously incubated Rocket Pharmaceuticals (NASDAQ: RCKT), which focuses on developing first-in-class gene therapies for rare and devastating, inherited genetic diseases.

For further information please visit rtwfunds.com.

In January 2024, Bayer announced an equity investment into CORXEL in the amount of USD 35 million. The collaboration will grant Bayer privileged rights to negotiate the commercialization of CORXEL’s pipeline assets in the areas of cardiovascular diseases and ophthalmology. In addition to tapping into Bayer’s deep experience in the cardiovascular and ophthalmology fields, the collaboration will leverage the company’s significant presence in China. Bayer and CORXEL will also form a joint portfolio strategy committee to explore potential additional business development opportunities, and Xiaolan Zhou, Executive Vice President, Pharmaceuticals Division, Bayer AG, President of Bayer Pharmaceuticals China, President of Bayer Greater China, will join CORXEL’s Board of Directors. 

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.4 billion euros. For more information, go to www.bayer.com.